AiwuRuthHeMD

Oncology • Washington, DC

Associate Professor, Medicine, Georgetown University School of Medicine

Join to view full profile

Dr. He is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. He's full profile

Already have an account?

Office
3800 Reservoir Rd Nw
Washington, DC 20007
Phone+1 202-444-2198

Summary

I am a board certified medical oncologist focus on GI cancer.

Education & Training

MedStart Georgetown University HospitalFellowship, Medical Oncology, 2004 - 2006
Hunan Medical UniversityClass of 1991

Certifications & Licensure

DC State Medical License 2004 - 2026
American Board of Internal Medicine Medical Oncology

Clinical Trials

Bispecific Antibody in Finding Tumor Cells in Patients With Colorectal Cancer Start of enrollment: 2008 Nov 01
Unknown status
Phase 1
Sunitinib and Capecitabine for First Line Colon Cancer
TERMINATED
PHASE2
ABT-888 and Temozolomide for Liver Cancer
TERMINATED
PHASE2
A Study of LY2157299 in Participants With Hepatocellular Carcinoma Start of enrollment: 2011 Mar 30
Completed
Phase 2
Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron Start of enrollment: 2017 Jul 05
Terminated
Phase 2
Defined Green Tea Catechin Extract in Preventing Liver Cancer in Participants With Cirrhosis Start of enrollment: 2018 Aug 09
ACTIVE_NOT_RECRUITING
PHASE1
Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC) Start of enrollment: 2020 Nov 30
Terminated
Phase 2
Roles: Principal Investigator, Contact, Sponsor-Investigator
Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma
WITHDRAWN
PHASE2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Combining Radioembolization and Immune Checkpoint Inhibitors for the Treatment of Hepatocellular Carcinoma: The Quest for Synergy.
Christopher D Malone, Suryansh Bajaj, Aiwu He, Kabir Mody, Ryan M Hickey
Journal of Vascular and Interventional Radiology. 2025-03-01
7 citations
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
George Lau, Ghassan K Abou-Alfa, Ann-Lii Cheng, Wattana Sukeepaisarnjaroen, Tu Van Dao
Journal of Hepatology. 2025-02-01
Longitudinal Circulating Tumor Cell Collection, Culture, and Characterization in Pancreatic Adenocarcinomas.
Jerry Xiao, Reetu Mukherji, George Sidarous, Shravanthy Suguru, Marcus Noel
Cancers. 2025-01-22

Press Mentions

SPTBN1 Inhibits Inflammatory Responses and Hepatocarcinogenesis via the Stabilization of SOCS1 and Downregulation of p65 in Hepatocellular CarcinomaFebruary 20th, 2021